Immatics N.V. is a biopharmaceutical company that develops immunotherapies for the treatment of cancer in the US. It focuses on treating solid tumors through adoptive cell therapies and antibody-like TCR Bispecifics. The company has several product candidates in Phase I clinical trials and preclinical studies, and a strategic collaboration agreement with multiple companies to develop novel adoptive cell therapies.